To include your compound in the COVID-19 Resource Center, submit it here.

Deal streak continues for Alexion as Achillion’s story hits $930M high note

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to build its pipeline beyond Soliris.

The takeout, announced Wednesday, would see Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) acquire Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) for $6.30 per share in cash, and give Alexion two complement inhibitors to supplement its leading position in paroxysmal nocturnal hemoglobinuria.

The deal is the culmination of a

Read the full 828 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE